News articles about XBiotech (NASDAQ:XBIT) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. XBiotech earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.4355491292002 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

XBiotech (NASDAQ XBIT) traded up $0.03 during trading on Friday, reaching $4.16. 70,198 shares of the company traded hands, compared to its average volume of 93,173. XBiotech has a 12-month low of $2.77 and a 12-month high of $20.18. The stock has a market cap of $146.36, a P/E ratio of -2.55 and a beta of 0.54.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact XBiotech (XBIT) Stock Price” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-xbiotech-xbit-stock-price.html.

XBiotech Company Profile

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Insider Buying and Selling by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Stock Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related stocks with our FREE daily email newsletter.